Evercore ISI Cuts Henry Schein (NASDAQ:HSIC) Price Target to $70.00

Henry Schein (NASDAQ:HSIC) had its target price reduced by equities researchers at Evercore ISI from $72.00 to $70.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “in-line” rating on the stock. Evercore ISI’s target price points to a potential upside of 4.71% from the company’s current price.

Several other equities analysts have also commented on the stock. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Piper Sandler reissued an “overweight” rating and set a $86.00 price target on shares of Henry Schein in a research report on Friday, June 21st. Barrington Research reduced their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday. UBS Group reduced their price target on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, May 8th. Finally, Robert W. Baird raised shares of Henry Schein from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $81.00 to $92.00 in a research report on Monday, July 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Henry Schein has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Henry Schein Stock Performance

Shares of Henry Schein stock traded up $2.93 during midday trading on Wednesday, hitting $66.85. The company had a trading volume of 954,557 shares, compared to its average volume of 1,199,150. The stock has a market cap of $8.56 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.80 and a beta of 0.87. The company has a quick ratio of 1.02, a current ratio of 1.75 and a debt-to-equity ratio of 0.47. The company has a fifty day simple moving average of $67.84 and a 200 day simple moving average of $71.68. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.22 by $0.01. The firm had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. Henry Schein’s revenue was up .0% on a year-over-year basis. During the same period last year, the firm posted $1.31 EPS. As a group, analysts predict that Henry Schein will post 5.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. LGT Group Foundation grew its stake in shares of Henry Schein by 21.9% during the 2nd quarter. LGT Group Foundation now owns 192,770 shares of the company’s stock worth $12,357,000 after purchasing an additional 34,579 shares during the period. Quest Partners LLC acquired a new stake in shares of Henry Schein during the 2nd quarter worth approximately $177,000. Acadian Asset Management LLC grew its stake in shares of Henry Schein by 10.2% during the 2nd quarter. Acadian Asset Management LLC now owns 3,757 shares of the company’s stock worth $240,000 after purchasing an additional 348 shares during the period. National Bank of Canada FI grew its stake in shares of Henry Schein by 15.5% during the 2nd quarter. National Bank of Canada FI now owns 43,769 shares of the company’s stock worth $2,850,000 after purchasing an additional 5,860 shares during the period. Finally, Versor Investments LP acquired a new stake in Henry Schein in the 2nd quarter valued at $527,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.